Clinical trial · Observational
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epigenetic | — | UNRESOLVED | — |
| Metastasis | Pancreatic Neoplasm | PROBABILISTIC | 0.70 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Non-responder
- description
- Patients who do not respond to the FOLFIRINOX regimen.
- label
- Responder
- description
- Patients who respond to the FOLFIRINOX regimen.
Primary outcomes (2)
- measure
- Response to treatment
- timeFrame
- After 4 cycle of therapy (each cycle is 15 days)
- description
- Response to FOLFIRINOX treatment after 4 cycles of therapy.
- measure
- Response to treatment
- timeFrame
- After the 8 cycle of therapy (each cycle is 15 days)
- description
- Response to FOLFIRINOX treatment after 8 cycles of therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with metastatic PDAC; * Patients who will start treatment with FOLFIRINOX; * 18 years or older; * Who agree to participate in the study by signing the Informed Consent Form; Exclusion Criteria: * Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment; * Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
References
Publications (0)
Data not yet available